{
  "attach_pages": "3",
  "attach_size": "450",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP202008041396354059_1.pdf?1596562178000.pdf",
  "company_code": "80000197",
  "eitime": "2020-08-04 17:29:38",
  "extend": {},
  "info_code": "AP202008041396354059",
  "language": "0",
  "notice_date": "2020-08-04 00:00:00",
  "notice_title": "中报点评：业绩季度环比改善，股权激励注入长期发展动力",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "沈文文",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "恒瑞医药",
      "short_name_ch": "恒瑞医药",
      "short_name_cht": "恒瑞醫藥",
      "short_name_en": "HENGRUI PHARMA",
      "stock": "600276"
    }
  ],
  "short_name": "恒瑞医药",
  "source_sample_name": "中航证券",
  "star": "1"
}